PACE is the first phase 3 randomized trial directly comparing radical prostatectomy with SBRT in men with low- to intermediate-risk prostate cancer.

Continuous glucose monitoring yields modest reductions in hemoglobin A1c levels in adults with type 2 diabetes compared with standard care.

Elevated maternal body mass index and excessive weight gain during pregnancy increase the risk of early-onset CVD in offspring.

Glucagon-like peptide-1 receptor agonists improve obstructive sleep apnea outcomes in obesity, primarily through significant ...

Tirzepatide therapy reduces the risk for major adverse cardiovascular events in patients with type 2 diabetes and established CVD.

The FDA has approved Bravnetsa (lutetium Lu 177 dotatate) via the ANDA pathway as a bioequivalent treatment option for SSTR-positive GEP-NETs.

The FDA has approved Degevma (denosumab-adet), a new biosimilar to Xgeva, to prevent skeletal-related events in patients with bone metastases.

The Endocrine Society successfully blocked an FTC subpoena regarding its gender-affirming care guidelines following a federal court injunction.

FDA grants Priority Review to Bayer’s sNDA for elinzanetant (Lynkuet) to treat moderate to severe vasomotor symptoms from endocrine therapy in breast cancer.

IBD is not associated with increased risk for hypertensive disorders of pregnancy, but is associated with increased risk for preeclampsia.

Few women initiate systemic hormone therapy for menopausal symptoms, and the majority of patients who do discontinue treatment within the first year.

Isolated diastolic hypertension in young adults is associated with an increased risk for atherosclerotic cardiovascular disease and heart failure.